Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic ALK alterations in primary and relapsed neuroblastoma.
Rosswog C, Fassunke J, Ernst A, Schömig-Markiefka B, Merkelbach-Bruse S, Bartenhagen C, Cartolano M, Ackermann S, Theissen J, Blattner-Johnson M, Jones B, Schramm K, Altmüller J, Nürnberg P, Ortmann M, Berthold F, Peifer M, Büttner R, Westermann F, Schulte JH, Simon T, Hero B, Fischer M. Rosswog C, et al. Among authors: schulte jh. Br J Cancer. 2023 Apr;128(8):1559-1571. doi: 10.1038/s41416-023-02208-y. Epub 2023 Feb 17. Br J Cancer. 2023. PMID: 36807339 Free PMC article.
Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature.
De Preter K, Vermeulen J, Brors B, Delattre O, Eggert A, Fischer M, Janoueix-Lerosey I, Lavarino C, Maris JM, Mora J, Nakagawara A, Oberthuer A, Ohira M, Schleiermacher G, Schramm A, Schulte JH, Wang Q, Westermann F, Speleman F, Vandesompele J. De Preter K, et al. Among authors: schulte jh. Clin Cancer Res. 2010 Mar 1;16(5):1532-41. doi: 10.1158/1078-0432.CCR-09-2607. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179214 Free article.
Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.
Ackermann S, Goeser F, Schulte JH, Schramm A, Ehemann V, Hero B, Eggert A, Berthold F, Fischer M. Ackermann S, et al. Among authors: schulte jh. Clin Cancer Res. 2011 Feb 15;17(4):731-41. doi: 10.1158/1078-0432.CCR-10-1129. Epub 2010 Dec 17. Clin Cancer Res. 2011. PMID: 21169242
High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma.
Schulte JH, Bachmann HS, Brockmeyer B, Depreter K, Oberthür A, Ackermann S, Kahlert Y, Pajtler K, Theissen J, Westermann F, Vandesompele J, Speleman F, Berthold F, Eggert A, Brors B, Hero B, Schramm A, Fischer M. Schulte JH, et al. Clin Cancer Res. 2011 Aug 1;17(15):5082-92. doi: 10.1158/1078-0432.CCR-10-2809. Epub 2011 Jun 1. Clin Cancer Res. 2011. PMID: 21632861
Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.
Heukamp LC, Thor T, Schramm A, De Preter K, Kumps C, De Wilde B, Odersky A, Peifer M, Lindner S, Spruessel A, Pattyn F, Mestdagh P, Menten B, Kuhfittig-Kulle S, Künkele A, König K, Meder L, Chatterjee S, Ullrich RT, Schulte S, Vandesompele J, Speleman F, Büttner R, Eggert A, Schulte JH. Heukamp LC, et al. Among authors: schulte s, schulte jh. Sci Transl Med. 2012 Jul 4;4(141):141ra91. doi: 10.1126/scitranslmed.3003967. Sci Transl Med. 2012. PMID: 22764207
Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome.
Schramm A, Schowe B, Fielitz K, Heilmann M, Martin M, Marschall T, Köster J, Vandesompele J, Vermeulen J, de Preter K, Koster J, Versteeg R, Noguera R, Speleman F, Rahmann S, Eggert A, Morik K, Schulte JH. Schramm A, et al. Among authors: schulte jh. Br J Cancer. 2012 Oct 9;107(8):1409-17. doi: 10.1038/bjc.2012.391. Br J Cancer. 2012. PMID: 23047593 Free PMC article.
MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma.
Lodrini M, Oehme I, Schroeder C, Milde T, Schier MC, Kopp-Schneider A, Schulte JH, Fischer M, De Preter K, Pattyn F, Castoldi M, Muckenthaler MU, Kulozik AE, Westermann F, Witt O, Deubzer HE. Lodrini M, et al. Among authors: schulte jh. Nucleic Acids Res. 2013 Jul;41(12):6018-33. doi: 10.1093/nar/gkt346. Epub 2013 Apr 26. Nucleic Acids Res. 2013. PMID: 23625969 Free PMC article.
Targeted Therapy for Neuroblastoma: ALK Inhibitors.
Schulte JH, Schulte S, Heukamp LC, Astrahantseff K, Stephan H, Fischer M, Schramm A, Eggert A. Schulte JH, et al. Among authors: schulte s. Klin Padiatr. 2013 Nov;225(6):303-8. doi: 10.1055/s-0033-1357132. Epub 2013 Oct 28. Klin Padiatr. 2013. PMID: 24166094 Review.
p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
Dreidax D, Bannert S, Henrich KO, Schröder C, Bender S, Oakes CC, Lindner S, Schulte JH, Duffy D, Schwarzl T, Saadati M, Ehemann V, Benner A, Pfister S, Fischer M, Westermann F. Dreidax D, et al. Among authors: schulte jh. Hum Mol Genet. 2014 Dec 20;23(25):6826-37. doi: 10.1093/hmg/ddu406. Epub 2014 Aug 7. Hum Mol Genet. 2014. PMID: 25104850
212 results